Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic

Brain metastasis of lung cancer is one of the most important metastasis pathways in patients with life-threatening diseases. This study explore the efficacy and safety of Tislelizumab combining with platinum-containing drug chemotherapy in the first-line treatment of Lung Adenocarcinoma With Asymptomatic Brain Metastatic. Meanwhile, Related biomarkers were explored to provide theoretical basis for efficacy evaluation and resistance mechanism.

Trial Details

NCT ID
NCT06056115
Phase
NA
Sponsor
Hebei Medical University Fourth Hospital
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Tislelizumab,Platinum
Locations (sample)
  • Shijiazhuang, Hebei, China|38.04139,114.47861

Key Eligibility Criteria

  • Patients with metastatic (stage IV) lung adenocarcinoma who have not been systematically treated and are histologically or cytologically confirmed …
  • Patients with brain metastases confirmed by imaging;
  • Patients with asymptomatic BMS after initial diagnosis, local BMS surgery or radiotherapy;
  • ECOG PS: 0-1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →